Avelumab plus axitinib (A plus Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial

被引：0

作者：

Oya, M. ^{[1
]}

Motzer, R. J. ^{[2
]}

Choueiri, T. K. ^{[3
]}

Haanen, J. B. A. G. ^{[4
]}

Eto, M. ^{[5
]}

Uemura, H. ^{[6
]}

Venugopal, B. ^{[7
]}

Rini, B. I. ^{[8
]}

Miyake, H. ^{[9
]}

Albiges, L. ^{[10
]}

Schmidinger, M. ^{[11
]}

Tomita, Y. ^{[12
,13
]}

Umeyama, Y. ^{[14
]}

Ellers-Lenz, B. ^{[15
]}

Hoffman, J. ^{[16
]}

Larkin, J. ^{[17
]}

机构：

[1] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

[4] Netherlands Canc Inst, Amsterdam, Netherlands

[5] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan

[6] Kindai Univ, Fac Med, Dept Urol, Osakasayama, Japan

[7] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[8] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[9] Kobe Univ, Grad Sch Med, Div Urol, Kobe, Hyogo, Japan

[10] Inst Gustave Roussy, Villejuif, France

[11] Med Univ Vienna, Vienna, Austria

[12] Niigata Univ, Grad Sch Med, Dept Urol, Niigata, Japan

[13] Niigata Univ, Grad Sch Med, Dept Mol Oncol, Niigata, Japan

[14] Pfizer Japan Inc, Clin & Res Dept, Oncol, Shibuya Ku, Tokyo, Japan

[15] Merck Healthcare KGaA, Darmstadt, Germany

[16] EMD Serono Res & Dev Inst Inc, Billerica, MA USA

[17] Royal Marsden Hosp, London, England

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.312

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

292P

引用

页码：S1517 / S1518

页数：2

共 50 条

[41] Final Analysis of Post-Marketing Surveillance for Avelumab plus Axitinib in Patients With Renal Cell Carcinoma in Japan
Nonomura, Norio
Ito, Taito
Sato, Masashi
Morita, Makiko
Ogi, Mie
Kajita, Masahiro
Oya, Mototsugu
CANCER MEDICINE, 2025, 14 (02):
[42] Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial
Grunwald, Viktor
Motzer, Robert J.
Keizman, Daniel
Bedke, Jens
Schmidinger, Manuela
Staehler, Michael D.
Matveev, Vsevolod B.
George, Saby
Hutson, Thomas E.
Vaishampayan, Ulka N.
Merchan, Jaime R.
Eto, Masatoshi
Rha, Sun Young
Waddell, Tom
Sabbatini, Roberto
Barthelemy, Philippe
Burgents, Joseph E.
Ren, Min
Brown, Ian
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
Motzer, R. J.
Choueiri, T.
Larkin, J.
Albiges, L.
Haanen, J. B.
Schmidinger, M.
Atkins, M. B.
Mariani, M.
Shnaidman, M.
Di Pietro, A.
Rini, B. I.
ANNALS OF ONCOLOGY, 2016, 27
[44] Axitinib in combination with pembrolizumab (AXI plus PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers
Atkins, Michael
Martini, Jean-Francois
Plimack, Elizabeth
McDermott, David
Puzanov, Igor
Fishman, Mayer
Cho, Daniel
Vaishampayan, Ulka
Rosbrook, Brad
Fernandez, Kathrine
Tarazi, Jamal
George, Saby
Choueiri, Toni
CANCER RESEARCH, 2019, 79 (13)
[45] A UK real-world observational study of avelumab plus axitinib (A plus Ax) in advanced renal cell carcinoma (aRCC): Outcomes at 36 months post treatment initiation.
Nathan, Paul D.
Charnley, Natalie
Frazer, Ricky
McGrane, John
Muazzam, Iqtedar
Pillai, Manon
Rudman, Sarah
Stevenson, Robert
Venugopal, Balaji
Hickey, Joseph David
Ritchie, Aimi Rose
Liu, Kin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 386 - 386
[46] Avelumab plus axitinib (Ave plus Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Venugopal, B.
Choueiri, T. K.
Penkov, K. D.
Albiges, L.
Uemura, H.
Larkin, J.
Tomita, Y.
Wang, J.
Hoffman, J.
Gerhold-Ay, A.
Kieslich, P.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2024, 35 : S1017 - S1018
[47] Post-marketing surveillance data for avelumab plus axitinib treatment in patients with advanced renal cell carcinoma in Japan: Subgroup analyses by pathological classification
Nonomura, Norio
Ito, Taito
Sato, Masashi
Morita, Makiko
Kajita, Masahiro
Oya, Mototsugu
INTERNATIONAL JOURNAL OF UROLOGY, 2025, 32 (03) : 293 - 299
[48] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
Porta, C. G.
Eto, M.
Motzer, R. J.
De Giorgi, U. F. F.
Buchler, T.
Basappa, N. S.
Mendez Vidal, M. J.
Tjulandin, S.
Park, S. H.
Melichar, B.
Hutson, T. E.
Alemany, C.
McGregor, B.
He, C. S.
Perini, R.
Mody, K.
McKenzie, J.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1205 - +
[49] Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
Motzer, Robert J.
Porta, Camillo
Eto, Masatoshi
Powles, Thomas
Gruenwald, Viktor
Hutson, Thomas E.
Alekseev, Boris
Rha, Sun Young
Merchan, Jaime R.
Goh, Jeffrey C.
Kapoor, Anil
De Giorgi, Ugo
Melichar, Bohuslav
Hong, Sung-Hoo
Gurney, Howard
Rodriguez-Lopez, Karla
He, Cixin S.
Okpara, Chinyere
McKenzie, Jodi
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] Characterization of response to nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214
Rini, B. I.
Tannir, N. M.
Escudier, B.
McDermott, D. F.
Grimm, M-O.
Porta, C.
Powles, T.
Kollmannsberger, C. K.
Gurney, H. P.
Tykodi, S. S.
Harrison, M.
Heng, D. Y. C.
Gruenwald, V.
Choueiri, T. K.
Mekan, S.
McHenry, M. B.
Hammers, H. J.
Motzer, R. J.
George, S.
ANNALS OF ONCOLOGY, 2018, 29

← 1 2 3 4 5 →